BidaskClub cut shares of Tabula Rasa HealthCare (NASDAQ:TRHC) from a buy rating to a hold rating in a research report sent to investors on Saturday.
A number of other research analysts also recently issued reports on TRHC. Robert W. Baird reiterated a buy rating and set a $70.00 target price on shares of Tabula Rasa HealthCare in a research report on Wednesday, August 8th. Piper Jaffray Companies boosted their target price on shares of Tabula Rasa HealthCare to $71.00 and gave the company an overweight rating in a research report on Wednesday, August 8th. Citigroup boosted their target price on shares of Tabula Rasa HealthCare from $57.00 to $76.00 and gave the company a buy rating in a research report on Thursday, August 9th. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a hold rating to a buy rating and set a $74.00 price objective on the stock in a report on Saturday, August 11th. Finally, Oppenheimer upped their price objective on shares of Tabula Rasa HealthCare from $65.00 to $86.00 and gave the stock an outperform rating in a report on Thursday, August 23rd. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $75.82.
Tabula Rasa HealthCare stock opened at $71.77 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.33 and a current ratio of 0.36. Tabula Rasa HealthCare has a 12-month low of $26.02 and a 12-month high of $91.16. The firm has a market cap of $1.36 billion, a P/E ratio of -1,794.25, a P/E/G ratio of 5.06 and a beta of 2.85.
In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction on Friday, August 17th. The shares were sold at an average price of $72.23, for a total transaction of $577,840.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 48,000 shares of company stock worth $3,630,240. Corporate insiders own 14.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mount Yale Investment Advisors LLC acquired a new position in Tabula Rasa HealthCare during the second quarter worth $111,000. Meadow Creek Investment Management LLC bought a new stake in shares of Tabula Rasa HealthCare in the 2nd quarter worth $115,000. Envestnet Asset Management Inc. bought a new stake in shares of Tabula Rasa HealthCare in the 2nd quarter worth $130,000. Mckinley Capital Management LLC Delaware grew its stake in shares of Tabula Rasa HealthCare by 60.5% in the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 2,431 shares of the company’s stock worth $155,000 after acquiring an additional 916 shares in the last quarter. Finally, Pinebridge Investments L.P. bought a new stake in shares of Tabula Rasa HealthCare in the 2nd quarter worth $181,000. Hedge funds and other institutional investors own 75.17% of the company’s stock.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Further Reading: Tariff
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.